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Summary: Pseudouridine is a modified nucleoside derived from RNA catabolism; the concentration of this nucleo-
side is elevated in body fluids of both tumour-bearing and human immunodeficiency virus (HIV) infected patients.
We used an HPLC procedure to evaluate the serum pseudouridine concentration in patients with chronic hepatitis
C in an attempt to determine whether the nucleoside serum concentration was related to the response to a-in-
terferon treatment.
We found that:
a) pseudouridine serum concentration was increased significantly in 76% (29/39) of patients with chronic hepatitis
C at the time of diagnosis and before any therapeutic treatment;
b) pseudouridine excretion was higher in patients affected by chronic hepatitis C with cirrhosis;
c) there was a positive correlation between response to therapy and pseudouridine serum concentration in patients
undergoing treatment with a-interferon;
d) during one year of α-interferon treatment, the pseudouridine serum concentration remained within the normal
range in responder patients.
These results indicate that serum pseudouridine might be useful as a valuable biochemical marker with which to
monitor chronic hepatitis C patients treated with a-interferon.
Introduction further degraded, but is excreted as an end product of
Hepatitis C virus is the most important causative agent RNA catabolism C7); consequently, pseudouridine is
of non-A, non-B hepatitis (1); the infection tends to excreted Changed and is thus a faithful index of RNA
become chronic and to progress to cirrhosis and/or tammer <*>' Numerous ^dies have shown that when
hepatocellular carcinoma (2). TTie virus contains a pos- ^^T^ 'S TeaSed' as dunngneoplasuc growth
itive-stranded RNA genome with only one open read- or fflV mfectlon>the «Hwenttehon of pseudoundme m
~ j· r - τ ι * · body f l u i d s increases (9-16).mg frame encoding for a single polyprotein precursor J ^ '
of 3011 amino acids that is cleaved into three struc- We evaluated serum pseudouridine concentrations in pa-
tural proteins and four non-structural enzymatic pro- tients with chronic hepatitis C to determine whether vi-
teins (3). ral RNA metabolism (duplication and/or translation)
Interferons are a heterogeneous family of glycoprotems causes chan8es in Pseudouridine concentration, and
with antiviral and antiproliferative activity (4); α-in- whether such chan§es reflect the Passion of the in-
terferon has been shown to normalize aminotransferase fection> L e' we ^tennined the potential value of pseu-
levels and reduce disease activity in a significant douridine as a biochemical marker m the monitoring of
number of patients affected by chronic hepatitis C (5). chrollic hePatitis C Patients treated with interferon'
Interferon treatment is a long-term therapy and can
cause adverse effects. Therefore, it is critical to monitor Materials and Methods
the response to therapy in order to adjust therapeutic controls
" * Twenty-six apparently healthy volunteers of both sexes, from the
Pseudouridine, a modified nucleoside derived from Clinical Biochemistry Department of the School of Mediae
_ _ . , XT . . . . tanzaro, Italy, were enrolled as controls. They were not taking any
RNA degradation, mainly tRNA, is detectable in mam- dmgSj their serum values for various biochemical quantities were
malian body fluids (6). It is not reutilized by the cell or normal, and they were negative for hepatitis C virus RNA.
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Patients
Sixty-five consecutive subjects (32 males and 33 females, mean
age 51.9 ± 13.3; age range 14-80) affected by active chronic hep-
atitis C of different historically determined severity, attending
the Infectious Disease Out-Patient Unit of the School of Medicine,
Catanzaro, were enrolled in the study. Twenty-one of these patients
received α-interferon treatment; 38 patients without cirrhosis and
6 with active hepatitis C virus cirrhosis, all at the time of diagnosis,
were untreated.
The disease was diagnosed from histological examination of percu-
taneous liver biopsy specimens according to conventional .criteria.
Anti-hepatitis C virus antibody was detected by second generation
enzyme-linked immunosorbent assay, and serum viral RNA was
detected with the polymerase chain reaction technique. Patients
with autoimmune hepatitis, alcoholic or drug-related liver disease,
haemochromatosis, Wilson's disease or arantiproteinase defi-
ciency were excluded. The biochemical tests also used for exclu-
sion, were: bilirubin > 51.3 μηηοΐ/ΐ, albumin < 30 g/1, prothrombin
time > 3 s longer than that of the control, serum creatinine > 150
μτηοΐ/ΐ, platelet count < 100 X 109/1, granulocyte count < 1.5
X 109/1. The study protocols were approved by the local ethics
committee and informed consent to the study was obtained from
each patient.
Sample collection
Venous blood was collected into vacutainers tube (Becton Dickin-
son, Milan, Italy) and centrifuged within 2 h of withdrawal; alanine
and aspartate aminotransferase were analysed thereafter. Aliquots
of serum samples were stored at —80 °C until pseudouridine analy-
sis. Alanine and aspartate aminotransferase were assayed with a
Cobas Mira S analyser (Roche Diagnostic Systems, Milan, Italy)
using reagents from Roche.
Hepatit is C virus RNA detection
The serum of those patients positive for anti-hepatitis C virus anti-
body by second generation enzyme-linked immunosorbent assay
(ELISA Ortho Diagnostic, Milan, Italy), was then tested for hepati-
tis C virus-RNA, using Amplicore HCV (Roche Diagnostic Sys-
tems, Milan, Italy).
Treatment with a-interferon
Twenty-one patients (10 males and 11 females) with active chronic
hepatitis C, showing an increase of alanine aminotransferase of at
least twice the upper limit of the reference range for more than 6
months, received 3 MU of recombinant interferon a-2b (Intron A)
subcutaneously three times a week for 3 months. Patients who re-
sponded to treatment, i. e., return to normal serum alanine amino-
transferase levels, received 3 MU of α-interferon for another 9
months and then 2 MU for 2 months and 1 MU for 1 month. Non-
responder subjects, after the first three months of treatment, were
given a second cycle of α-interferon at 6 MU for 6 months; if their
serum alanine aminotransferase levels normalized, they underwent
a protocol with decreasing doses. Therapy was stopped in non-
responder subjects. Pseudouridine serum concentrations were mea-
sured at 1, 3, 6 and 12 months from the beginning of interferon
therapy.
Pseudouridine determination
Serum pseudouridine was measured as previously described (17).
Briefly, 0.5 ml of serum was deproteinized with an equal volume
of cold acetonitrile, kept on ice for 15 min and centrifuged at
3000 g for 10 min. Nucleosides were purified by affinity chroma-
tography on phenylboronic gel (Affigel 601, Bio Rad Laboratories,
Segrate, Italy) equilibrated with 0.25 mol/1 ammonium acetate, pH
8.5. Nucleosides were eluted with 15 ml of 0.1 mol/1 formic acid;
2.5 nmol/250 μΐ of 2'-deoxyguanosine were added as internal stan-
dard, after which the samples were lyophilized. Aliquots of 25 μΐ
were injected onto a C18^Bondapack column (Waters Associates,
USA) in an HPLC HP 1050 system (Hewlett Packard, USA). The
column was eluted with 10 mmol/1 NH4H2P04 solution containing
60 ml of CH3OH per litre at a flow-rate of 1 ml/min. Pseudouridine
peaks were recorded and integrated with a 3396 HP system. All
the reagents were of HPLC grade.
Statistics
The means and standard deviations were computed for each vari-
able. The ANOVA "one-way" analysis of the variance (Epistat pro-
gram) was used to evaluate significance.
Results , f
In the 26 controls the serum concentrations of pseudo-
uridine, aspartate aminotransferase and alanine amino-
transferase were 2.6 ± 0.2 mmol/1, 25 ± 13 U/l and 23
± 16 U/l, respectively. This was in good agreement with
the reference range of pseudouridine previously found
in a healthy population from Italy and the United States
(18). The pseudouridine cut-off level was set at the mean
value plus 2 S.D. of normal controls (3.0 μιηοΐ/ΐ).
The pseudouridine serum concentrations determined in
the 38 patients with chronic hepatitis C at diagnosis and
before any treatment are shown in table 1. Serum pseu-
douridine was higher in 29 (76%) of these 38 patients
than in the control group, and serum aminotransferase
levels were in the reference range.
Of the 21 patients treated with α-interferon, 12 re-
sponded to treatment and 9 did not. Table 2 shows the
mean values of pseudouridine, alanine and aspartate
aminotransferase in the 12 responders and in the 9 non-
responders. In the 12 responder patients normalization
of aminotransferase paralleled the decrease in pseudo-
uridine concentration to the reference range. In contrast,
pseudouridine concentration increased significantly in
non-responder patients. The highest serum pseudouri-
dine concentrations were found in the 6 patients with
chronic C hepatitis which had evolved to liver cirrhosis.
Table 3 shows the profile of alanine aminotransferase
and pseudouridine concentrations in the serum of seven
responder patients from the time of diagnosis until 12
months after the start of treatment. Both analytes de-
Tab. 1 Aspartate aminotransferase, alanine aminotransferase and
pseudouridine serum concentrations in 38 patients with chronic


































a average of three determinations
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creased gradually during treatment, although the greatest
decrease occurred in the first month of α-interferon ther-
apy. It is noteworthy that pseudouridine concentration
preceded the normalization of alanine aminotransferase,
in fact the pseudouridine concentrations had already de-
creased to reference values after the first month of treat-
ment, while alanine aminotransferase was stationary.
Discussion
Interferon is currently becoming the treatment of choice
in chronic hepatitis C virus infection. However, the re-
sponse to interferon treatment is heterogeneous, and is
probably related to viral strain, genetic factors or host
immunity (19, 20). Moreover, there is as yet no labora-
tory test giving an early prediction of the success or
otherwise of interferon therapy. Currently, the response
to treatment is evaluated from the normalization of se-
rum alanine aminotransferase and the loss of virus from
the serum as detected by quantitative polymerase chain
reaction (PCR) of hepatitis C virus-RNA. However,
PCR is still far from being a routine test, because of the
lack of standardization, risk of contamination and poor
automation. Other markers, such as the Knodell index,
procollagen III and anti-hepatitis C virus antibodies, are
under study and may serve as adjunctive markers of
treatment response (21, 22).
We examined the relationship between pseudouridine
serum concentration and the response to a-interferon
treatment in patients with chronic hepatitis C to assess
the possibility of using pseudouridine, a catabolic RNA
index, as a biochemical marker of the replicative block-
age of the viral cycle induced by interferon. We deter-
mined the serum pseudouridine concentration in patients
with chronic hepatitis C at initial diagnosis and before
any therapeutic treatment, to evaluate the correlation of
the elevation of the nucleoside with the disease activity.
Pseudouridine levels were significantly elevated in 76%
of the patients, and even higher levels were found in six
patients with liver cirrhosis. The elevation of the nucleo-
side in the 6 cirrhotics agrees with a study in which the
pseudouridine concentration increased when cirrhosis
evolved to hepatocellular carcinoma (23). Possibly these
patients with advanced disease are in transition phase
to hepatocellular carcinoma, or they could already have
developed an undetectable small cancer.
A significant decrease in pseudouridine serum levels oc-
curred only in cases of an effective response to a-in-
terferon treatment (responder patients), thus revealing a
good correlation between the response to the therapy
and the nucleoside serum concentration. Long-term (12
months) therapy monitoring showed that the pseudouri-
dine serum concentration decreased soon after the begin-
ning of α-interferon therapy and much earlier than ala-
nine aminotransferase normalization.
Elevated excretion of pseudouridine has been demon-
strated in patients with various malignancies (8—16), al-
though the biochemical basis of this phenomenon is un-
clear. That the increase in pseudouridine level is disease-
related and not caused by tissue destruction is supported
by the observation that in cancer patients the elevated
excretion of pseudouridine and other modified nucleo-
sides is the consequence of a higher turnover rate of
tRNA in tumour tissue than in the corresponding normal
tissue (24). It is not unreasonable to suppose that the
excretion of pseudouridine in patients infected by hepa-
Tab. 2 Serum aminotransferase and pseudouridine concentrations in patients undergoing α-interferon































a without α-interferon treatment
The results are the means of pseudouridine determinations at 1 and/or 3 months of
α-interferon treatment.
Tab. 3 Alanine aminotransferase and pseudouridine concentrations in seven responder patients during
a 12-month follow-up period.
Interferon treatment (months3)
Before
Alanine aminotransferase (U/l ± S. D.)



























a from the beginning of α-interferon treatment
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titis C virus is increased. In fact, although the mecha-
nisms of intracellular hepatitis C virus replication have
not yet been clarified, it seems conceivable that, since
hepatitis C virus is a positive-stranded RNA virus, early
molecular events of the virus cycle such as the transla-
tion of the viral proteins, are accompanied by an en-
hanced turnover-rate of the RNA populations involved.
Furthermore, the activity of enzymes involved in nucleo-
side metabolism appears to be increased in cirrhotic sub-
jects (25) and HIV patients excrete elevated levels of
pseudouridine (8, 16). Lastly, the structure of the geno-
mic HCV region encoding the E2 envelope protein is
similar to that of HIV gp!20 envelope protein (26).
In conclusion, given the correlation between serum
pseudouridine levels and the effective responses to a-
interferon treatment of patients with chronic hepatitis C,
and given the simplicity and accuracy of the methodol-
ogy, serum pseudouridine might be clinically useful as a
marker of the response to interferon treatment in chronic
hepatitis C. However, a more extended investigation on
a greater number of patients is needed to verify this hy-
pothesis and to evaluate the possible predictive value of
pseudouridine for the response to c^interferon treatment.
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